Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

PARP

2 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology · Bioinfo & AI

Biallelic loss of RB1 in hepatocellular carcinoma as synthetic lethal target for artificial intelligence-guided therapy

An J, Kim W, Zhang X, et al.

Signal transduction and targeted therapy

This study characterized biallelic inactivation of the RB1 tumor suppressor gene (RB1-Bi) in hepatocellular carcinoma (HCC), finding it in 14.6% of patients and associating it with significantly reduced overall survival. A deep learning model (FR-MIL) was developed to accurately predict RB1-Bi status from routine histopathology slides. High-throughput drug screenings revealed that RB1-Bi HCC cells are particularly sensitive to inhibitors targeting mitotic regulators and PARP inhibitors. These synthetic lethal interactions were validated in vitro and in vivo, suggesting RB1-Bi is an actionable biomarker for precision medicine in HCC.

Clinical

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer

Weiner-Gorzel K, McSorley L, Walshe JM

Current treatment options in oncology

Improved survival rates for reproductive-age breast cancer patients highlight significant oncofertility challenges. Fertility preservation, gonadotoxicity, and pregnancy safety are key concerns requiring early and integrated management within the therapeutic plan. Prompt referral for fertility preservation is crucial, ensuring it does not compromise oncologic outcomes. Modern therapies such as PARP inhibitors, CDK4/6 inhibitors, HER2-monoclonal antibodies, and endocrine treatments raise specific questions due to a lack of prospective human fertility data. A precautionary approach is recommended, including effective contraception and adherence to washout periods.